Effect of clomiphene citrate on human spermatozoal motility and fertilizing capacity in vitro

Identification of estrogen receptor protein and messenger ribonucleic acid in human spermatozoa

OBJECTIVE

The processes leading to fertilization involve a series of sequential events including the deposition and transport of sperm in the female genital tract. It is becoming evident that spermatozoa in which a hyperactive state has been induced are more effective in both reaching and penetrating the oocyte. Many of the changes that spermatozoa undergo are the result of their ability to respond to the milieu of the female genital tract. In the presence of estrogen sperm have been shown to have increased their metabolic activity and flagellar activity and to have an increased ability to penetrate oocytes. Most important, these observed changes in sperm physiology occur quickly, suggesting a novel second-messenger system coupled to the estrogen receptor. Established effects of steroid hormones involve mediation of the signal through genomic expression. However, because it has not been definitively demonstrated whether the human sperm express the estrogen receptor, the mechanism by which estrogen exert its effect remains to be elucidated.

STUDY DESIGN

The presence of estrogen receptors on human spermatozoa was investigated. Immunohistochemistry performed on human spermatozoa indicates that the estrogen receptors are located on the tailpiece. In addition, protein from human spermatozoa was isolated and subjected to Western blot analysis.

RESULTS

Results indicate a single band of approximately 65 kd, similar to that of the native human estrogen receptor. Ribonucleic acid obtained from the human spermatozoa was reverse transcribed into deoxyribonucleic acid. With use of selected primers, this deoxyribonucleic acid was amplified by polymerase chain reaction. Resolution and examination of the expansion products demonstrated a single band of deoxyribonucleic acid of 450 bp, identical to that expected from the selected primers. The specificity of this reverse transcriptase-polymerase chain reaction amplified deoxyribonucleic acid sequence was verified by Southern blotting.

CONCLUSION

For the first time we provide evidence as to the expression of estrogen receptor by human spermatozoa.

Spermatozoal fertilizing capacity in polyzoospermia: a preliminary study

Men with the spermatological symptom of polyzoospermia (greater than 250 X 10(6) sperm/ml) have been reported to seldom impregnate their wives. It was the aim of this study to investigate the spermatozoal fertilizing capacity in polyzoospermia by the human sperm and zona-free hamster ova penetration bioassay. General semen characteristics and in vitro spermatozoal fertilizing capacity were studied in 12 polyzoospermic male partners of couples of infertile marriages. The results were compared with those from a control group of normospermic fertile men (n = 22). No significant differences in sperm motility, normal morphology and in vitro spermatozoal fertilizing capacity were found between the two groups. The polyzoospermic men we studied did not appear to have any defect with the spermatozoal fertilizing capacity, as assessed by the heterologous sperm--ova penetration bioassay. The apparent impairment of fertility and higher abortion rate in couples with polyzoospermic male partners, as described in the literature, may be related to chromosomal aberrations and/or other unknown functional defect of the spermatozoa.

Seminal plasma beta-human chorionic gonadotropin (beta-HCG): relationships with seminal characteristics and spermatozoal fertilizing capacity

Seminal plasma beta-human chorionic gonadotropin (beta-HCG) levels were determined in 254 semen samples collected from fertile and suspected subfertile men, and their relationships with seminal characteristics and spermatozoal fertilizing capacity were evaluated. Radioimmunoassayable beta-HCG, as defined by greater than 5 mIU/ml concentration, was demonstrated in only 44.5% of all the samples studied. beta-HCG concentrations were similar in normospermic, oligospermic and azoospermic samples. There were no significant differences in beta-HCG concentration between high-motility and low-motility samples, between normal-morphology and abnormal-morphology samples, and between high-fertilizing capacity and low-fertilizing capacity samples. No significant correlations between the concentrations of beta-HCG and individual parameters of semen analysis and spermatozoal fertilizing capacity among the various groups of samples were observed. The physiological role of seminal plasma beta-HCG is presently uncertain and the relationship of its determination to male fertility requires further investigation.

Embryo toxicity of clomiphene citrate on mouse embryos fertilized in vitro and in vivo

The effect of the ovulatory agent clomiphene citrate on fertilization and early embryogenesis was investigated with the use of in vitro fertilized mouse oocytes. Alterations in early embryogenesis with clomiphene citrate exposure were further studied with the use of embryos obtained from mouse oocytes fertilized in vivo. In the nontreated group, the fertilization rate was 81%, and 61% of the oocytes reached the blastocyst stage by 96 hours. Both fertilization and blastocyst formation declined in a dose-dependent fashion when clomiphene citrate was added to the culture media in concentrations greater than or equal to 10 micrograms/ml (p less than 0.001). The rate of progressive embryo cleavage was also slower at 48 and 72 hours after drug exposure. Mouse embryos fertilized in vivo demonstrated similar findings, with decreased blastocyst formation and increased degeneration rates, again at clomiphene citrate concentrations greater than or equal to 10 micrograms/ml (p less than 0.01). Exposure to the drug beyond 24 hours had no additional effect. It appears that clomiphene citrate-exposed embryos may undergo subtle changes that later manifest themselves in the form of decreased embryo growth rates and increased embryo degeneration rates.

Clomiphene citrate does not improve spermatozoal fertilizing capacity in idiopathic oligospermia

Clomiphene citrate (CC) was given to 24 men with idiopathic oligospermia at a daily dose of 25 mg (10 subjects) or 50 mg (14 subjects). Sperm concentration increased slightly after CC treatment in both groups. Sperm motility and morphology remained unchanged. Spermatozoal fertilizing capacity as assessed by the zona-free hamster ova penetration test showed no significant change throughout the treatment period. Two pregnancies occurred in the partners of the subjects treated with 50 mg CC/day, but none occurred in the other group. We conclude that oral administration of CC does not improve fertilizing capacity of sperm as measured by the zona-free hamster ova penetration test in idiopathic oligospermia.